Navigation Links
Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
Date:7/22/2014

BETHLEHEM, Pa., July 22, 2014 /PRNewswire/ -- Eyeon Therapeutics has received a Notice of Allowance on a novel dry eye treatment based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO.  The product has been shown to be safe and effective in a small trial previously published.  Mark Mitchnick, MD, CEO states, "This first set of claims around the polymer and its class will go a long way to moving this technology into the commercial phase.  We have been using it in several development projects, and we believe it has promise in many ocular formulations as well as in other areas.  Helping Eyeon gain a proprietary position in this very important market is a great example of what Particle Sciences offers its partners." 

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few therapies.  Our product offers a unique approach that is clinically validated and useful in a number of ocular applications.  In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons." 

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at dave@eyeontherapeutics.com

Contact:
Maureen Grieco
610-861-4701
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Measuring Systems® Celebrates 40 Years of Leadership
2. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
3. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
4. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
5. Varian Medical Systems Signs Purchase Agreement with Advanced Particle Therapy LLC to Supply Technology for the Georgia Proton Treatment Center to be operated by Emory Healthcare
6. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
7. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Waters Introduces CORTECS Columns Featuring Solid-Core Particle Technology
10. HORIBA Scientific Launches New Raman ParticleFinder Software
11. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):